No Detail Found!

Efficacy and Safety of Dapagliflozin on Diabetic Patients Receiving High-doses of Insulin.

Author(s)
Meltem Sertbas Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Yasar Sertbas Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Nalan Okuroglu Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Ali Burkan Akyildiz Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Seda Sancak Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Ali Ozdemir Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Abstract
Objective: In this study we aimed to investigate the efficacy and safety of dapagliflozin addition to diabetic patients using high dose insulin. Methods: The current study was carried out in the outpatient diabetic clinics of Fatih Sultan Mehmet Education and Research Hospital. Thirty diabetic patients who were receiving high dose (>0.5U/kg) insulin and oral antidiabetic treatment (other than SGLT 2 inhibitors) were included in this study. Primary end point was the change in HbA1c, insulin doses and serum electrolyte from the addition of dapagliflozin 10 mg to the week 12. Results: At the end of three month BMI were obviously decreased from 33.31±4.51 to 32.14±4.66 (p: 0.001). There was also an evident decrease of insulin requirement from 76±23.15 U/kg to 57.60±17.61 U/ day (p0.05). Conclusion: In diabetic patients with inadequately controlled glucose regulation despite high-dose insulin therapy, dapagliflozin may be an alternative combination choice to decrease the need of insulin dose and obtain an optimal HbA1c, fasting plasma glucose levels and weight without major side effects.
Publication Details
Page(s) 399-403
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 35, Issue: 2, Year: 2019

Request the full text from PASTIC

0

Citations

0

Downloads

88

Views